Sign inJoin waitlistJoin the waitlist

Elias Jabbour

Chief, Section of Acute Lymphoblastic Leukemia · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Section of Acute Lymphoblastic Leukemia Division · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2003–2005
Gustave Roussy Institute
2001–2003
Saint Joseph University
1998–2001
Doctor of Medicine
1994–1998

Research

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · 2,489 citations
Acute myeloid leukemia: current progress and future directions
Review · Blood Cancer Journal · 2021 · 639 citations
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome
Cancer · 2006 · 524 citations

Hagop Kantarjian
740 papers
Guillermo Garcia-Manero
407 papers
Tapan Kadia
356 papers · 1 as a fellow
Jorge Cortes
335 papers
GB
Gautam Borthakur
306 papers
Naval Daver
284 papers
Nicholas Short
279 papers · 32 as a fellow
Marina Konopleva
236 papers
Courtney DiNardo
224 papers
Nitin Jain
212 papers · 1 as a fellow
KS
Koji Sasaki
197 papers · 28 as a fellow
Naveen Pemmaraju
193 papers · 1 as a fellow

Clinical trials

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Principal investigator · Not yet recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2031
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2032
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2033
A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2026–2033